PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease

Background Cognitive impairment in humans with Alzheimer's disease (AD) and in animal models of A&bgr;‐pathology can be ameliorated by treatments with the nuclear receptor peroxisome proliferator‐activated receptor‐gamma (PPAR&ggr;) agonists, such as rosiglitazone (RSG). Previously, we demonstrated that in the Tg2576 animal model of AD, RSG treatment rescued cognitive deficits and reduced aberrant activity of granule neurons in the dentate gyrus (DG), an area critical for memory formation. Methods We used a combination of mass spectrometry, confocal imaging, electrophysiology and split‐luciferase assay and in vitro phosphorylation and Ingenuity Pathway Analysis. Results Using an unbiased, quantitative nano‐LC‐MS/MS screening, we searched for potential molecular targets of the RSG‐dependent rescue of DG granule neurons. We found that S226 phosphorylation of fibroblast growth factor 14 (FGF14), an accessory protein of the voltage‐gated Na+ (Nav) channels required for neuronal firing, was reduced in Tg2576 mice upon treatment with RSG. Using confocal microscopy, we confirmed that the Tg2576 condition decreased PanNav channels at the AIS of the DG, and that RSG treatment of Tg2576 mice reversed the reduction in PanNav channels. Analysis from previously published data sets identified correlative changes in action potential kinetics in RSG‐treated T2576 compared to untreated and wildtype controls. In vitro phosphorylation and mass spectrometry confirmed that the multifunctional kinase GSK–3&bgr;, a downstream target of insulin signaling highly implicated in AD, phosphorylated FGF14 at S226. Assembly of the FGF14:Nav1.6 channel complex and functional regulation of Nav1.6‐mediated currents by FGF14 was impaired by a phosphosilent S226A mutation. Bioinformatics pathway analysis of mass spectrometry and biochemistry data revealed a highly interconnected network encompassing PPAR&ggr;, FGF14, SCN8A (Nav 1.6), and the kinases GSK–3 &bgr;, casein kinase 2&bgr;, and ERK1/2. Conclusions These results identify FGF14 as a potential PPAR&ggr;‐sensitive target controlling A&bgr;‐induced dysfunctions of neuronal activity in the DG underlying memory loss in early AD. HighlightsPhosphorylation of FGF14 at S226 in Tg2576 animals is reduced by rosiglitazone (RSG).Tg2576 condition decreases PanNav channels at AIS, which is reversed by RSG.GSK‐3&bgr; phosphorylates FGF14 at S226.Assembly of FGF14:Nav1.6 channel complex is reduced by a S226A mutationFunctional regulation of Nav1.6‐mediated currents was impaired by a S226A mutation.

[1]  M. Mobashir,et al.  Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease. , 2016, European journal of medicinal chemistry.

[2]  S. Stoilova-McPhie,et al.  Bioluminescence methodology for the detection of protein-protein interactions within the voltage-gated sodium channel macromolecular complex. , 2012, Assay and drug development technologies.

[3]  H. Manji,et al.  AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. , 2004, The international journal of neuropsychopharmacology.

[4]  B. Penninx,et al.  A Fine-Mapping Study of 7 Top Scoring Genes from a GWAS for Major Depressive Disorder , 2012, PloS one.

[5]  J. del Río,et al.  Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. , 2009, Biochemical and biophysical research communications.

[6]  E. ter Haar,et al.  Structure of GSK3beta reveals a primed phosphorylation mechanism. , 2001, Nature structural biology.

[7]  Je-Hyun Baek,et al.  Reciprocal Changes in Phosphorylation and Methylation of Mammalian Brain Sodium Channels in Response to Seizures* , 2014, The Journal of Biological Chemistry.

[8]  A. García-Osta,et al.  Rosiglitazone Rescues Memory Impairment in Alzheimer's Transgenic Mice: Mechanisms Involving a Reduced Amyloid and Tau Pathology , 2010, Neuropsychopharmacology.

[9]  G. Abecasis,et al.  Fine Mapping on Chromosome 13q32–34 and Brain Expression Analysis Implicates MYO16 in Schizophrenia , 2014, Neuropsychopharmacology.

[10]  K. Hsu,et al.  Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways , 2011, Neuropharmacology.

[11]  H. Manji,et al.  AR-A 014418 , a selective GSK-3 inhibitor , produces antidepressant-like effects in the forced swim test , 2004 .

[12]  Norelle C. Wildburger,et al.  Control of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase , 2012, Front. Mol. Neurosci..

[13]  I. Torres-Aleman,et al.  Astrocytes require insulin-like growth factor I to protect neurons against oxidative injury , 2014, F1000Research.

[14]  H. Hanyu,et al.  Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease , 2011, Neurobiology of Aging.

[15]  S. Michnick,et al.  A highly sensitive protein-protein interaction assay based on Gaussia luciferase , 2006, Nature Methods.

[16]  G. Terstappen,et al.  Therapeutic targets for Alzheimer's disease , 2009, Expert opinion on therapeutic targets.

[17]  G. Landreth,et al.  Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease , 2012, The Journal of Neuroscience.

[18]  M. Mohammadi,et al.  Crystal Structure of a Fibroblast Growth Factor Homologous Factor (FHF) Defines a Conserved Surface on FHFs for Binding and Modulation of Voltage-gated Sodium Channels* , 2009, The Journal of Biological Chemistry.

[19]  Syed R Ali,et al.  Identification of Amino Acid Residues in Fibroblast Growth Factor 14 (FGF14) Required for Structure-Function Interactions with Voltage-gated Sodium Channel Nav1.6* , 2016, The Journal of Biological Chemistry.

[20]  W. Honer,et al.  Linkage of familial schizophrenia to chromosome 13q32. , 1999, American journal of human genetics.

[21]  G. Aghajanian,et al.  GSK-3 Inhibition Potentiates the Synaptogenic and Antidepressant-Like Effects of Subthreshold Doses of Ketamine , 2013, Neuropsychopharmacology.

[22]  Lin Xu,et al.  Impaired hippocampal synaptic transmission and plasticity in mice lacking fibroblast growth factor 14 , 2007, Molecular and Cellular Neuroscience.

[23]  M. Grubb,et al.  Building and maintaining the axon initial segment , 2010, Current Opinion in Neurobiology.

[24]  J. Nerbonne,et al.  FGF14 N-terminal splice variants differentially modulate Nav1.2 and Nav1.6-encoded sodium channels , 2009, Molecular and Cellular Neuroscience.

[25]  W. Harrington,et al.  The Effect of PPARα, PPARδ, PPARγ, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice , 2007, PPAR research.

[26]  J. O'Donnell,et al.  Phosphodiesterase-4D Knock-Out and RNA Interference-Mediated Knock-Down Enhance Memory and Increase Hippocampal Neurogenesis via Increased cAMP Signaling , 2011, The Journal of Neuroscience.

[27]  N. Ip,et al.  Scapinin-induced Inhibition of Axon Elongation Is Attenuated by Phosphorylation and Translocation to the Cytoplasm , 2011, The Journal of Biological Chemistry.

[28]  R. Sadygov,et al.  Detection of structural and metabolic changes in traumatically injured hippocampus by quantitative differential proteomics. , 2013, Journal of neurotrauma.

[29]  E. Emamian AKT/GSK3 signaling pathway and schizophrenia , 2012, Front. Mol. Neurosci..

[30]  Paul M. Thompson,et al.  Detecting genetic risk factors for Alzheimer's disease in whole genome sequence data via Lasso screening , 2015, 2015 IEEE 12th International Symposium on Biomedical Imaging (ISBI).

[31]  G. Wilcock,et al.  The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.

[32]  S. Lane,et al.  PPARγ agonism attenuates cocaine cue reactivity , 2018, Addiction biology.

[33]  F. Duffy,et al.  Copy number variation plays an important role in clinical epilepsy , 2014, Annals of neurology.

[34]  J. Nerbonne,et al.  The FGF14F145S Mutation Disrupts the Interaction of FGF14 with Voltage-Gated Na+ Channels and Impairs Neuronal Excitability , 2007, The Journal of Neuroscience.

[35]  D. Wozniak,et al.  Impaired spatial learning and defective theta burst induced LTP in mice lacking fibroblast growth factor 14 , 2007, Neurobiology of Disease.

[36]  J. Radulovic,et al.  The role of hippocampal signaling cascades in consolidation of fear memory , 2004, Behavioural Brain Research.

[37]  F. Laezza,et al.  Intraneuronal Aβ accumulation induces hippocampal neuron hyperexcitability through A-type K+ current inhibition mediated by activation of caspases and GSK-3 , 2015, Neurobiology of Aging.

[38]  L. Denner,et al.  Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status , 2011, Behavioural Brain Research.

[39]  D. Wozniak,et al.  Ataxia and Paroxysmal Dyskinesia in Mice Lacking Axonally Transported FGF14 , 2002, Neuron.

[40]  R. Sadygov,et al.  Cognitive Enhancing Treatment with a PPARγ Agonist Normalizes Dentate Granule Cell Presynaptic Function in Tg2576 APP Mice , 2014, The Journal of Neuroscience.

[41]  G. Taglialatela,et al.  A method to determine insulin responsiveness in synaptosomes isolated from frozen brain tissue , 2016, Journal of Neuroscience Methods.

[42]  J. Nerbonne,et al.  FGF14 localization and organization of the axon initial segment , 2013, Molecular and Cellular Neuroscience.

[43]  M. Reger,et al.  Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[44]  O. Andersen,et al.  Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery , 2011, The Journal of general physiology.

[45]  Rovshan G Sadygov,et al.  Using power spectrum analysis to evaluate (18)O-water labeling data acquired from low resolution mass spectrometers. , 2010, Journal of proteome research.

[46]  D. Chuang,et al.  Lentivirally mediated GSK-3β silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice. , 2011, The international journal of neuropsychopharmacology.

[47]  J. David Sweatt,et al.  The MAPK cascade is required for mammalian associative learning , 1998, Nature Neuroscience.

[48]  E. Koroś,et al.  The role of glycogen synthase kinase-3beta in schizophrenia. , 2007, Drug news & perspectives.

[49]  M. Mann,et al.  Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.

[50]  J. A. Nogueira-Machado,et al.  Rosiglitazone, a PPAR-γ agonist, inhibits VEGF secretion by peripheral blood mononuclear cells and ROS production by human leukocytes , 2011, Inflammation Research.

[51]  Neli I Panova-Elektronova,et al.  Parallel fiber to Purkinje cell synaptic impairment in a mouse model of spinocerebellar ataxia type 27 , 2015, Front. Cell. Neurosci..

[52]  P. Blandina,et al.  Donepezil, an acetylcholine esterase inhibitor, and ABT-239, a histamine H3 receptor antagonist/inverse agonist, require the integrity of brain histamine system to exert biochemical and procognitive effects in the mouse , 2016, Neuropharmacology.

[53]  Elmar Krieger,et al.  A Mutation in the Fibroblast Growth Factor 14 Gene Is Associated with Autosomal Dominant Cerebral Ataxia , 2003 .

[54]  P. Heutink,et al.  Spinocerebellar ataxia associated with a mutation in the fibroblast growth factor 14 gene (SCA27): A new phenotype , 2006, Movement disorders : official journal of the Movement Disorder Society.

[55]  Arturo Pujia,et al.  Possible implications of insulin resistance and glucose metabolism in Alzheimer’s disease pathogenesis , 2011, Journal of cellular and molecular medicine.

[56]  A. Gingras,et al.  Systematic investigation of hierarchical phosphorylation by protein kinase CK2. , 2015, Journal of proteomics.

[57]  Christoph W. Blau,et al.  Rosiglitazone attenuates the age-related changes in astrocytosis and the deficit in LTP , 2012, Neurobiology of Aging.

[58]  M. Oellerich,et al.  Phosphoproteome profiling of substantia nigra and cortex regions of Alzheimer’s disease patients , 2012, Journal of neurochemistry.

[59]  K. Kwong,et al.  Voltage-gated sodium channels. , 2015, Current opinion in pharmacology.

[60]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[61]  C. Landry,et al.  A toolkit of protein-fragment complementation assays for studying and dissecting large-scale and dynamic protein-protein interactions in living cells. , 2010, Methods in enzymology.

[62]  Amanda J. Foust,et al.  The spatio‐temporal characteristics of action potential initiation in layer 5 pyramidal neurons: a voltage imaging study , 2011, The Journal of physiology.

[63]  Alexandre P. Blanchard,et al.  Phosphoproteome analysis of an early onset mouse model (TgCRND8) of Alzheimer's disease reveals temporal changes in neuronal and glia signaling pathways , 2013, Proteomics.

[64]  D. Ornitz,et al.  Subcellular and developmental expression of alternatively spliced forms of fibroblast growth factor 14 , 2000, Mechanisms of Development.

[65]  R. Sadygov,et al.  Cognitive Enhancement with Rosiglitazone Links the Hippocampal PPARγ and ERK MAPK Signaling Pathways , 2012, The Journal of Neuroscience.

[66]  J. Nerbonne,et al.  Fibroblast growth factor 14 is an intracellular modulator of voltage‐gated sodium channels , 2005, The Journal of physiology.

[67]  C. Ruivenkamp,et al.  A new variable phenotype in spinocerebellar ataxia 27 (SCA 27) caused by a deletion in the FGF14 gene. , 2014, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[68]  Jesús Avila,et al.  Role of glycogen synthase kinase-3 in Alzheimer’s disease pathogenesis and glycogen synthase kinase-3 inhibitors , 2010, Expert review of neurotherapeutics.

[69]  F. Tempia,et al.  Impaired Firing Properties of Dentate Granule Neurons in an Alzheimer's Disease Animal Model Are Rescued by Ppar␥ Agonism , 2022 .

[70]  C. Nilsson,et al.  Role of the Axonal Initial Segment in Psychiatric Disorders: Function, Dysfunction, and Intervention , 2014, Front. Psychiatry.

[71]  M. Roh,et al.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. , 2006, Current drug targets.

[72]  E. Hoxha,et al.  Genetic deletion of fibroblast growth factor 14 recapitulates phenotypic alterations underlying cognitive impairment associated with schizophrenia , 2016, Translational psychiatry.

[73]  David Piwnica-Worms,et al.  Current state of imaging protein-protein interactions in vivo with genetically encoded reporters. , 2007, Annual review of biomedical engineering.

[74]  Elmar Krieger,et al.  A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebellar ataxia [corrected]. , 2003, American journal of human genetics.

[75]  Suzanne R. Kalb,et al.  Assembly Protein Precursor (pUL80.5 Homolog) of Simian Cytomegalovirus Is Phosphorylated at a Glycogen Synthase Kinase 3 Site and Its Downstream “Priming” Site: Phosphorylation Affects Interactions of Protein with Itself and with Major Capsid Protein , 2004, Journal of Virology.

[76]  Richard D. LeDuc,et al.  Quantitative Proteomics Reveals Protein–Protein Interactions with Fibroblast Growth Factor 12 as a Component of the Voltage-Gated Sodium Channel 1.2 (Nav1.2) Macromolecular Complex in Mammalian Brain , 2015, Molecular & Cellular Proteomics.

[77]  L. Swenson,et al.  Structure of GSK3β reveals a primed phosphorylation mechanism , 2001, Nature Structural Biology.

[78]  David B. Goldstein,et al.  A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia , 2009, PLoS genetics.

[79]  J. Sweatt,et al.  Mitogen-activated protein kinases in synaptic plasticity and memory , 2004, Current Opinion in Neurobiology.

[80]  William A Catterall,et al.  Voltage‐gated sodium channels at 60: structure, function and pathophysiology , 2012, The Journal of physiology.

[81]  A. De Luca,et al.  Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery , 2016, Front. Pharmacol..

[82]  M. Pérez,et al.  Therapeutic Actions of the Thiazolidinediones in Alzheimer's Disease , 2015, PPAR research.

[83]  I. Torres-Aleman,et al.  Astrocytes require insulin-like growth factor I to protect neurons against oxidative injury. , 2014, F1000Research.

[84]  Norelle C. Wildburger,et al.  The Fibroblast Growth Factor 14·Voltage-gated Sodium Channel Complex Is a New Target of Glycogen Synthase Kinase 3 (GSK3)* , 2013, The Journal of Biological Chemistry.

[85]  G. Breen,et al.  Linkage Replication for Chromosomal Region 13q32 in Schizophrenia: Evidence from a Brazilian Pilot Study on Early Onset Schizophrenia Families , 2012, PloS one.

[86]  I. Gaisina,et al.  Glycogen Synthase Kinase-3 Is a Functional Modulator of Serotonin-1 B Receptors , 2011 .

[87]  Zayd M. Khaliq,et al.  Relative Contributions of Axonal and Somatic Na Channels to Action Potential Initiation in Cerebellar Purkinje Neurons , 2006, The Journal of Neuroscience.

[88]  S. Zaitone,et al.  Pioglitazone and exenatide enhance cognition and downregulate hippocampal beta amyloid oligomer and microglia expression in insulin-resistant rats. , 2016, Canadian journal of physiology and pharmacology.

[89]  C. Ong,et al.  Luteolin induces G1 arrest in human nasopharyngeal carcinoma cells via the Akt-GSK-3β-Cyclin D1 pathway. , 2010, Cancer letters.

[90]  F. Laezza,et al.  Fibroblast Growth Factor 14 Modulates the Neurogenesis of Granule Neurons in the Adult Dentate Gyrus , 2016, Molecular Neurobiology.

[91]  J. Trimmer,et al.  Multisite phosphorylation of voltage-gated sodium channel alpha subunits from rat brain. , 2010, Journal of proteome research.

[92]  Mert R. Sabuncu,et al.  Machine Learning and Medical Imaging , 2016 .

[93]  Shaun P Jackson,et al.  Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. , 2007, The Biochemical journal.

[94]  M. Berk,et al.  The Putative Use of Lithium in Alzheimer's Disease. , 2016, Current Alzheimer research.

[95]  F. Laezza,et al.  Intracellular Fibroblast Growth Factor 14: Emerging Risk Factor for Brain Disorders , 2017, Front. Cell. Neurosci..

[96]  F. Laezza,et al.  Improved Methods for Fluorescence Microscopy Detection of Macromolecules at the Axon Initial Segment , 2016, Front. Cell. Neurosci..

[97]  D. Piwnica-Worms,et al.  Detection of protein-protein interactions in live cells and animals with split firefly luciferase protein fragment complementation. , 2008, Methods in molecular biology.

[98]  J. D. McGaugh Memory--a century of consolidation. , 2000, Science.

[99]  Shao Li,et al.  Elevated Neuronal Excitability Due to Modulation of the Voltage-Gated Sodium Channel Nav1.6 by Aβ1−42 , 2016, Front. Neurosci..

[100]  V. Bennett,et al.  Physiological roles of axonal ankyrins in survival of premyelinated axons and localization of voltage-gated sodium channels , 1999, Journal of neurocytology.

[101]  Manuela G. López,et al.  Involvement of PI3K, GSK-3β and PPARγ in the antidepressant-like effect of folic acid in the forced swimming test in mice , 2012, Journal of psychopharmacology.

[102]  R. Jope,et al.  Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and Therapeutics , 2007, Neurochemical Research.

[103]  Amanda J. Foust,et al.  Action Potentials Initiate in the Axon Initial Segment and Propagate through Axon Collaterals Reliably in Cerebellar Purkinje Neurons , 2010, The Journal of Neuroscience.

[104]  I. Módy,et al.  Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers via inhibition of inflammatory responses , 2014, Neuroscience Letters.

[105]  C. Matute Astrocytes require insulin-like growth factor I to protect neurons , 2019 .

[106]  Fernanda Laezza,et al.  Split-luciferase complementation assay to detect channel-protein interactions in live cells. , 2015, Methods in molecular biology.

[107]  Cheryl F. Lichti,et al.  CK2 activity is required for the interaction of FGF14 with voltage‐gated sodium channels and neuronal excitability , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[108]  W. Snider,et al.  Functions of GSK-3 Signaling in Development of the Nervous System , 2011, Front. Mol. Neurosci..

[109]  Hu-qing Wang,et al.  The PPARγ agonist rosiglitazone prevents cognitive impairment by inhibiting astrocyte activation and oxidative stress following pilocarpine-induced status epilepticus , 2012, Neurological Sciences.

[110]  Joseph L. Ransdell,et al.  Intracellular FGF14 (iFGF14) Is Required for Spontaneous and Evoked Firing in Cerebellar Purkinje Neurons and for Motor Coordination and Balance , 2015, The Journal of Neuroscience.

[111]  Cheryl F. Lichti,et al.  The Nav1.2 channel is regulated by GSK3. , 2015, Biochimica et biophysica acta.

[112]  M. Zhan,et al.  Identifying a Kinase Network Regulating FGF14:Nav1.6 Complex Assembly Using Split-Luciferase Complementation , 2015, PloS one.

[113]  L. Denner,et al.  PPARγ Recruitment to Active ERK during Memory Consolidation Is Required for Alzheimer's Disease-Related Cognitive Enhancement , 2014, The Journal of Neuroscience.

[114]  Michael H. F. Wilkinson,et al.  Digital Image Analysis of Microbes: Imaging, Morphometry, Fluorometry, and Motility Techniques and Applications , 1998 .

[115]  Christophe Leterrier,et al.  Protein kinase CK2 contributes to the organization of sodium channels in axonal membranes by regulating their interactions with ankyrin G , 2008, The Journal of cell biology.

[116]  J. Trimmer,et al.  Mass spectrometry-based phosphoproteomics reveals multisite phosphorylation on mammalian brain voltage-gated sodium and potassium channels. , 2011, Seminars in cell & developmental biology.

[117]  Syed R Ali,et al.  Modulation of the FGF14:FGF14 homodimer interaction through short peptide fragments. , 2014, CNS & neurological disorders drug targets.

[118]  A D Roses,et al.  Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease , 2006, The Pharmacogenomics Journal.